Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: Humana is a leading U.S. healthcare company operating through two primary segments: Insurance (Medicare Advantage, Medicaid, PDP, and specialty benefits) and CenterWell (pharmacy solutions, primary care, and home solutions). The company focuses on an integrated care delivery model to improve health outcomes and affordability.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Total Revenues | $40,867 | $80,515 | $64,500 |
| Net Income Attributable to Humana | $694 | $1,880 | $1,789 |
| Diluted EPS | $5.73 | $15.55 | $14.81 |
| Operating Cash Flow | N/A | $3,220 | $1,602 |
| Cash and Cash Equivalents | $6,893 (Balance) | $6,893 (Balance) | $4,200 (Balance) |
| Total Debt (Short + Long Term) | $14,247 (Balance) | $14,247 (Balance) | $12,369 (Balance) |
| Benefit Ratio | 91.1% | 90.2% | 88.4% |
| Operating Cost Ratio | 9.8% | 10.0% | 10.8% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26.2% year-over-year for the quarter and 24.8% for the six-month period. Premium revenue grew 26.4% (quarter) and 25.0% (six months), driven by significant membership growth in Medicare Advantage and stand-alone PDP products, higher per-member premiums, and increased Part D direct subsidies under the Inflation Reduction Act.
- Profitability: Net income attributable to Humana rose 27.3% for the quarter and 5.1% for the six-month period. However, the benefit ratio increased (worsened) by 140 basis points for the quarter and 180 basis points for the six-month period, primarily due to a "Bonus Year" 2026 Star Ratings revenue headwind and higher costs associated with new member enrollment.
- Acquisitions: On February 13, 2026, Humana acquired MaxHealth, a Florida-based primary care organization, for approximately $908 million in cash. This contributed to goodwill increases and higher operating costs in the CenterWell segment.
- Cost Management: Operating costs increased 12.2% for the quarter and 15.5% for the six-month period. Despite this, the operating cost ratio improved (decreased) due to operating leverage from revenue growth and cost-saving initiatives.
- Debt Structure: In March 2026, the company issued $1.0 billion in junior subordinated notes and utilized commercial paper, resulting in short-term debt of $2.268 billion at June 30, 2026, compared to zero at the end of 2025.
Guidance, Outlook, Risks, and Unusual Items
- Value Creation Initiatives: The company recorded charges of $56 million (quarter) and $154 million (six months) related to a multi-year transformation program involving severance, asset impairments, and consulting expenses. Additional charges are expected.
- Impairment Charges: Recorded $21 million in impairment charges related to minority-interest investments in the current period.
- Regulatory Risks (RADV): A significant contingency involves the Centers for Medicare and Medicaid Services (CMS) Risk-Adjustment Data Validation (RADV) audits. While a district court vacated the "Final RADV Rule" in September 2025, the government has appealed. The outcome could materially impact financial results if extrapolated recoveries without a "Fee-for-Service Adjuster" are enforced.
- Legal Proceedings: The company faces ongoing litigation, including a securities class action regarding financial performance statements, a shareholder derivative action, and a False Claims Act lawsuit regarding non-commission payments to brokers.
- Outlook: Management expects continued growth in membership and earnings but notes that the "Bonus Year" 2026 Star Ratings headwind and regulatory uncertainties remain key factors. The company maintains a BBB credit rating.
Investor Verification Checklist
- Star Ratings Impact: Verify the specific financial impact of the 2026 "Bonus Year" Star Ratings headwind on future premium revenue and the benefit ratio.
- RADV Litigation Status: Monitor the appeal of the district court decision vacating the Final RADV Rule, as a reversal could trigger significant reserve adjustments.
- MaxHealth Integration: Assess the integration progress and cost synergies of the $908 million MaxHealth acquisition, particularly its effect on the CenterWell segment's operating cost ratio.
- Debt Maturity Profile: Review the maturity schedule of the new $1.0 billion junior subordinated notes and the $1.3 billion commercial paper outstanding to evaluate refinancing risks.
- Benefit Ratio Trend: Analyze whether the increase in the benefit ratio (to 90.2% for the six months) is a temporary anomaly due to new member mix or a structural shift in medical cost trends.